Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00113516

Public ClinicalTrials.gov record NCT00113516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Study Of SU011248 As Consolidation Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).

Study identification

NCT ID
NCT00113516
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
84 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2005
Primary completion
Feb 28, 2009
Completion
Feb 28, 2009
Last update posted
May 17, 2010

2005 – 2009

United States locations

U.S. sites
27
U.S. states
8
U.S. cities
20
Facility City State ZIP Site status
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Newark Delaware 19713
Pfizer Investigational Site Newark Delaware 19718
Pfizer Investigational Site Wilmington Delaware 19899
Pfizer Investigational Site Maywood Illinois 60153
Pfizer Investigational Site Jeffersonville Indiana 47130
Pfizer Investigational Site Louisville Kentucky 40202
Pfizer Investigational Site Louisville Kentucky 40217
Pfizer Investigational Site Louisville Kentucky 40241
Pfizer Investigational Site Shelbyville Kentucky 40065
Pfizer Investigational Site Hershey Pennsylvania 17033
Pfizer Investigational Site Franklin Tennessee 37067
Pfizer Investigational Site Gallatin Tennessee 37066
Pfizer Investigational Site Hermitage Tennessee 37076
Pfizer Investigational Site Lebanon Tennessee 37087
Pfizer Investigational Site Murfreesboro Tennessee 37130
Pfizer Investigational Site Nashville Tennessee 37203-1632
Pfizer Investigational Site Nashville Tennessee 37203
Pfizer Investigational Site Nashville Tennessee 37205
Pfizer Investigational Site Nashville Tennessee 37207
Pfizer Investigational Site Nashville Tennessee 37211
Pfizer Investigational Site Smyrna Tennessee 37167
Pfizer Investigational Site Burleson Texas 76028
Pfizer Investigational Site Cleburne Texas 76031
Pfizer Investigational Site Fort Worth Texas 76104
Pfizer Investigational Site Mineral Wells Texas 76067
Pfizer Investigational Site Weatherford Texas 76086

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00113516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 17, 2010 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00113516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →